The neural stem and progenitor cells (NSCs and NPCs, respectively) found in the subventricular zone (SVZ) of the brain have the potential to replace damaged neuronal populations due to their ability to renew through cell division. These cells are therefore interesting targets for therapeutic manipulation in treatment of neurodegenerative diseases. Although the generation of new neurons from the SVZ occurs naturally, it is clear that in order to achieve therapeutically-relevant levels of neurogenesis, mechanisms such as localized delivery of growth factors to increase differentiation, migration and survival of new neurons from stem cell zones is required. The goal of this work is to develop a synthetic, biocompatible vector for efficient gene delivery to NPCs in the SVZ. The polymeric vector will incorporate multiple bioactive peptides to assist in NPC targeting and intracellular trafficking. Specifically, the peptide-functionalized polymer will include: (i) bioactive peptides for DNA condensation, cell targeting and endosomal escape, (ii) HPMA (N-(2- hydroxypropyl)methacrylamide) backbone for biocompatibility (iii) polyethylene glycol (PEG) for particle stabilization, and (iv) disulfide bonds for degradation after cellular internalization. The polymer composition will be optimized for high efficiency gene delivery to NPCs through in vitro transfection screening, and the mechanism of delivery investigated through flow cytometry, confocal microscopy and FRET analyses. In addition, the plasmid vector will be engineered for sustained transgene expression in NPCs that shuts down after the NPCs differentiate into mature neurons. The most promising vectors will be evaluated by intraventricular administration to mice in order to further optimize vectors for efficient in vivo delivery. The distribution of dual-labeled (plasmid and polymer) vectors after administration will be imaged by confocal microscopy of brain sections. In addition, the type of cells expressing the delivered transgene at various time points after transfection will be determined by fluorescent antibody staining of brain sections. Finally, the efficiency of in vivo gene transfer will be further enhanced by amplifying the number of dividing cells through localized growth factor delivery and by promoting neuron migration and survival by delivery of the BDNF (brain- derived neurotrophic factor) plasmid. If successful, the potential impact of this project is broad. The developed vectors could be used as vehicles to deliver therapeutic genes for treatment of neurogenerative CNS disorders.

Public Health Relevance

Neurogenerative diseases of the brain, such as Alzheimer's Disease, Huntington's Disease, and Parkinson's Disease, affect over 20 million people worldwide, and most current treatments for these diseases are palliative rather than restorative. One promising treatment approach to neurodegenerative disorders is the manipulation of neural stem and progenitor cells in the adult human nervous system to restore lost neuronal populations. The goal of this work is to develop synthetic gene delivery vectors that can be used to specifically deliver growth factors to neural progenitor cells in the brain in order to stimulate neurogenesis. The proposed approach involves incorporating bioactive peptides in the polymeric vector to promote targeting to the neural progenitor cells and efficient intracellular delivery. The developed technology would have broad significance as vehicles to deliver therapeutic genes for CNS disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS064404-04
Application #
8215909
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Owens, David F
Project Start
2009-02-15
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2014-01-31
Support Year
4
Fiscal Year
2012
Total Cost
$345,105
Indirect Cost
$130,730
Name
University of Washington
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wei, Hua; Volpatti, Lisa R; Sellers, Drew L et al. (2013) Dual responsive, stabilized nanoparticles for efficient in vivo plasmid delivery. Angew Chem Int Ed Engl 52:5377-81
Schellinger, Joan G; Pahang, Joshuel A; Shi, Julie et al. (2013) Block copolymers containing a hydrophobic domain of membrane-lytic peptides form micellar structures and are effective gene delivery agents. ACS Macro Lett 2:725-730
Chu, David S H; Schellinger, Joan G; Bocek, Michael J et al. (2013) Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery. Biomaterials 34:9632-7
Carlson, Peter M; Schellinger, Joan G; Pahang, Joshuel A et al. (2013) Comparative study of guanidine-based and lysine-based brush copolymers for plasmid delivery. Biomater Sci 1:736-744
Tsui, Jonathan H; Lee, Woohyuk; Pun, Suzie H et al. (2013) Microfluidics-assisted in vitro drug screening and carrier production. Adv Drug Deliv Rev 65:1575-88
Zhang, Lei; Sinclair, Andrew; Cao, Zhiqiang et al. (2013) Hydrolytic cationic ester microparticles for highly efficient DNA vaccine delivery. Small 9:3439-44
Shi, Julie; Chou, Brian; Choi, Jennifer L et al. (2013) Investigation of Polyethylenimine/DNA Polyplex Transfection to Cultured Cells Using Radiolabeling and Subcellular Fractionation Methods. Mol Pharm 10:2145-56
Shi, Julie; Choi, Jennifer L; Chou, Brian et al. (2013) Effect of polyplex morphology on cellular uptake, intracellular trafficking, and transgene expression. ACS Nano 7:10612-20
Shi, Julie; Schellinger, Joan G; Johnson, Russell N et al. (2013) Influence of histidine incorporation on buffer capacity and gene transfection efficiency of HPMA-co-oligolysine brush polymers. Biomacromolecules 14:1961-70
Wei, Hua; Pahang, Joshuel A; Pun, Suzie H (2013) Optimization of brush-like cationic copolymers for nonviral gene delivery. Biomacromolecules 14:275-84

Showing the most recent 10 out of 18 publications